Life-threatening events after theophylline overdose: A 10-year prospective analysis

Archives of Internal Medicine

Volumn 159, Issue 9, 1999, Pages 989-994

  Shannon, Michael ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

THEOPHYLLINE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTHMA; CARDIOTOXICITY; CHILD; DRUG BLOOD LEVEL; DRUG FATALITY; DRUG OVERDOSE; DRUG SAFETY; HEART ARRHYTHMIA; HUMAN; HUMAN CELL; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; NEWBORN; PRIORITY JOURNAL; SEIZURE; TREATMENT INDICATION; TREATMENT OUTCOME;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ARRHYTHMIA; BRONCHODILATOR AGENTS; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LONGITUDINAL STUDIES; MALE; MASSACHUSETTS; MIDDLE AGED; ODDS RATIO; OVERDOSE; PROSPECTIVE STUDIES; SEIZURES; THEOPHYLLINE;

EID: 0033542053     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.159.9.989     Document Type: Article

References (41)

1. Rossing TH. Methylxanthines in 1989. Ann Intern Med. 1989;110:502-504.
2. Strauss RE, Wertheim DL, Bonagura VR, Valacer DJ. Aminophylline therapy does not improve outcome and increases adverse effects in children hospitalized with acute asthmatic exacerbations. Pediatrics. 1994;93:205-210.
3. Eichenwald EC, Sina A, Stark AR. Apnea frequently persists beyond term gestation in infants delivered at 24-28 weeks. Pediatrics. 1997;100:354-359.
4. Davi M, Sankaran K, Simons K, Simons F, Seshia M, Rigatto H. Physiologic changes induced by theophylline in the treatment of apnea in preterm infants. J Pediatr. 1978;92:91-95.
5. Epstein PE. Hemlock or healer? the mercurial reputation of theophylline. Ann Intern Med. 1993;119:1216-1217.
6. Murciano D, Auclair M-H, Pariente R, Aubier M. A randomized, controlled trial of theophylline in patients with severe chronic obstructive pulmonary disease. N Engl J Med. 1989;320:1521-1525.
7. Weinberger M, Hendeles L. Theophylline in asthma. N Engl J Med. 1996;334: 1380-1388.
8. Dawson AH, Whyte IM. The assessment and treatment of theophylline poisoning. Med J Aust. 1989;151:689-693.
9. Knodel AR, Covelli HO, Beekman JF. Outpatient theophylline determinations. West J Med. 1984;140:741-744.
10. Schiff GD, Hegde HK, LaCloche L, Hryhorczuk DO. Inpatient theophylline toxicity: preventable factors. Ann Intern Med. 1991;114:748-753.
11. Derby LE, Jick SS, Langlois JC, Johnson LE, Jick H. Hospital admission for xanthine toxicity. Pharmacotherapy. 1990;10:112-114.
12. Litovitz TL, Smilkstein M, Felberg L, Klein-Schwartz W, Berlin R, Morgan JL. 1996 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1997;15:447-500.
13. Hall KW, Dobson KE, Dalton JG, Ghignone MC, Penner SB. Metabolic abnormalities associated with intentional theophylline overdose. Ann Intern Med. 1984; 101:457-462.
14. Bahls F, Ma KK, Bird TD. Theophylline-associated seizures with "therapeutic" or low toxic serum concentrations: risk factors for serious outcome in adults. Neurology. 1991;41:1309-1312.
15. Nakada T, Keww IL, Lerner AM, Remler MP. Theophylline-induced seizures: clinical and pathophysiologic aspects. West J Med. 1983;138:371-374.
16. Zwillich CW, Sutton FD, Neff TA, Cohn WM, Matthay RA, Weinberger MM. Theophylline-induced seizures in adults. Ann Intern Med. 1975;82:784-787.
17. Woody RC, Laney M. A second case of infantile intracranial hemorrhage and severe neurological sequelae following theophylline overdose. Dev Med Child Neurol. 1986;28:120-121.
18. American Academy of Pediatrics, Committee on Drugs. Precautions concerning the use of theophylline. Pediatrics. 1992;89:781-784.
19. Covelli HD, Knodel AR, Heppner BT. Predisposing factors to apparent theophylline-induced seizures. Ann Allergy. 1985;54:411-415.
20. Aitken ML, Martin TR. Life-threatening theophylline toxicity is not predictable by serum levels. Chest. 1987;91:10-14.
21. Shannon M, Lovejoy F. Effect of acute versus chronic intoxication on clinical features of theophylline poisoning in children. J Pediatr. 1992;121:125-130.
22. Shannon M. Predictors of major toxicity after theophylline overdose. Ann Intern Med. 1993;119:1161-1167.
23. Hendeles L, Jenkins J, Temple R. Revised PDA labeling guidelines for theophylline oral dosage forms. Pharmacotherapy. 1995;15:409-427.
24. Olson KR, Benowitz NL, Woo OF, Pond SM. Theophylline overdose: acute single ingestion versus chronic repeated overmedication. Am J Emerg Med. 1985;3: 386-394.
25. Shannon M, Lovejoy F. The influence of age vs peak serum concentration of life-threatening events after chronic theophylline intoxication. Arch Intern Med. 1990; 150:2045-2048.
26. Bertino JS, Walker JW. Reassessment of theophylline toxicity-serum concentrations, clinical course, and treatment. Arch Intern Med. 1987;147:757-760.
27. Stavric B. Methylxanthines: toxicity to humans. Food Chem Toxicol. 1988;26: 541-565.
28. Grigor RR, Spitz PW, Furst DE. Salicylate toxicity in elderly patients with rheumatoid arthritis. J Rheumatol. 1987;14:60-66.
29. Gaudreault P, Temple AR, Lovejoy FH. The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison. Pediatrics. 1982;70: 566-569.
30. Shkrum MJ, Gay RM, Hudson P. Fatal iatrogenic salicylate intoxication in a long-term user of enteric-coated aspirin. Arch Pathol Lab Med. 1989;113: 89-90.
31. Serafin WE. Drugs used in the treatment of asthma. In: Hardman J, Limbird L, Molinoff P, Ruddon R, Gilman A, eds. Goodman and Gilman's: The Pharmacological Basis of Therapeutics. New York, NY: McGraw-Hill: 1996:659-682.
32. Bittar G, Friedman HS. The arrhythmogenicity of theophylline: a multivariate analysis of clinical determinants. Chest. 1991;99:1415-1420.
33. Lin C-K, Chuand I-N, Cheng K-K, Chiang BN. Arrhythmogenic effects of theophylline in human atrial tissue. Int J Cardiol. 1987;17:289-297.
34. Curry SC, Vance MV, Requa R, Armstead R. Cardiovascular effects of toxic concentrations of theophylline in the dog. Ann Emerg Med. 1985;14:547-553.
35. Curry SC, Vance MV, Requa R, Armstead R. The effects of toxic concentrations of theophylline on oxygen consumption, ventricular work, acid base balance and plasma catecholamine levels in the dog. Ann Emerg Med. 1985;14:554-561.
36. Ujhelyi MR, Hulula G, Skau DA. Role of exogenous adenosine as a modulator of theophylline toxicity. Crit Care Med. 1994;22:1639-1646.
37. Wilson AN, Broadley KJ. Analysis of the direct and indirect effects of adenosine on atrial and ventricular cardiac muscle. Can J Physiol Pharmacol. 1989;67: 294-303.
38. vanBelle H. Nucleoside transport inhibition: a therapeutic approach to cardioprotection via adenosine? Cardiovasc Res. 1993;27:68-75.
39. Shannon M. Hypokalemia, hyperglycemia and plasma catecholamine activity after severe theophylline intoxication. Clin Toxicol. 1994;32:41-47.
40. Gaudreault P, Wason S, Lovejoy F. Acute pediatric theophylline overdose: a summary of 28 cases. J Pediatr. 1983;102:474-476.
41. Sessler CN. Theophylline toxicity: clinical features of 116 consecutive cases. Am J Med. 1990;88:567-576.